4.00
-0.1(-2.44%)
Currency In USD
Address
Craigmuir Chambers
Tortola, VG1110
Virgin Islands, British
Phone
203 221 7378
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
January 02, 2002
Name | Title | Pay | Year Born |
Dr. Ian B. Walters M.B.A., M.D. | Chief Executive Officer & Chairman of Board | 717,885 | 1968 |
Mr. Brian Wiley | Chief Business Officer | 155,422 | 1968 |
Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer | 185,891 | N/A |
Adam Melero | Controller | 0 | N/A |
Ms. Eun-Jae Park CPA | Chief Financial Officer | 0 | 1972 |
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.